x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

DarshanTalks Podcast

Darshan Kulkarni

Welcome to DarshanTalks!We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.We focus on life science issues involving

science life sciences

All Episodes

1:18

Key Regulatory Agencies in Pharma M&A

DarshanTalks Podcast ·

2025/02/20

When conducting an M&A transaction in the pharmaceutical or medical device industry, compliance must be a top priority. Regulatory agencies like the DOJ, FDA, OIG, and OCR have strengthened oversight, emphasizing successor liability and the need for strong compliance programs. Beyond FDA regulations, companies must consider fraud prevention, HIPAA, and evolving privacy laws at both federal and state levels. Ignoring these factors can lead to serious legal and financial consequences. Stay ...

en-us

1:37

Does E6 (R3) Blur the Line Between GCP and Privacy Laws?

DarshanTalks Podcast ·

2025/02/19

In this video, Edye Edens discusses the recent transition of ICH GCP E6 from R2 to R3, highlighting an interesting question she received: Is R3 evolving into a privacy doctrine? Given its increased focus on data protection, system validation, and privacy responsibilities, some wonder if it overlaps with regulatory frameworks like HIPAA, especially as OCR proposes significant updates to the Security Rule. However, Edens notes that while R3 contains more references to privacy, it does not expli...

en-us

8:01

RFK Jr. Confirmed as HHS Secretary: What It Means for...

DarshanTalks Podcast ·

2025/02/18

Edye Edens and Darshan Kulkarni dive into the confirmation of RFK Jr. as Secretary of Health and Human Services and the immediate impact of President Trump’s latest executive order. The order mandates a comprehensive national health assessment, addressing issues like obesity, diabetes, and pediatric disorders, and aims to reshape the country’s approach to preventive care. While the focus on public health challenges is timely, the broad and vague nature of the directive raises questions about ...

en-us

7:44

America’s Research Future in Jeopardy

DarshanTalks Podcast ·

2025/02/15

Darshan Kulkarni and Edye Edens break down the significant impact of the Trump administration’s decision to cut NIH funding and reduce agency workforces, including the FDA, OHRP, and other key regulatory bodies. They discuss how these cuts could lead to serious disruptions in research funding, approval timelines, and the overall pace of medical innovation in the U.S. While some argue that such reductions could improve efficiency and reduce waste, others fear the immediate and long-term conseq...

en-us

7:48

Trump Administration’s NIH cuts: Will they cripple US...

DarshanTalks Podcast ·

2025/02/14

Darshan Kulkarni and Edye Edens discuss the recent controversy surrounding the Trump administration’s decision to cap NIH overhead funding (also known as indirect costs or F&A) at 15%. This sweeping change has already sparked significant backlash, with academic medical centers, particularly in Democratic states, filing lawsuits to challenge the policy. The cap threatens to disrupt funding structures that support essential research, potentially undermining the United States’ role as a glob...

en-us

7:47

DEI Under Trump: What It Means for Clinical Trials

DarshanTalks Podcast ·

2025/02/13

The Trump administration’s early actions have significantly impacted federally funded programs, particularly in the clinical trial space, by rolling back diversity, equity, and inclusion (DEI) initiatives. This shift raises serious concerns for scientific research, as diversity in clinical trials ensures that drugs and devices are effective across different populations. Historically, most approved treatments have been tested primarily on white males, creating gaps in data for other demographi...

en-us

1:39

CAPA & RCA: A Must for Pharma M&A

DarshanTalks Podcast ·

2025/02/12

When acquiring a pharmaceutical company, evaluating its quality and compliance programs is crucial. A strong program starts with well-documented policies and procedures, followed by comprehensive training to ensure employees understand and follow them. However, having policies in place isn’t enough—regulatory bodies like the FDA and DOJ stress that enforcement and documentation are essential. If an issue isn’t written down, it effectively never happened. No regulator expects perfection, but t...

en-us

1:21

Trump Targets Indirect Costs in NIH Funding

DarshanTalks Podcast ·

2025/02/11

On Friday, the Trump administration announced a 15% cap on NIH indirect costs, raising important questions about its impact on research funding. Edye Edens breaks down what this means, clarifying that while direct costs like salaries and equipment remain unchanged, the cap affects crucial behind-the-scenes expenses such as lab maintenance, IT infrastructure, cybersecurity, and compliance. Understanding these distinctions is key as institutions adapt—watch as Edye unpacks the details. Support ...

en-us

2:29

The USAID Halt and Its Consequences for Clinical...

DarshanTalks Podcast ·

2025/02/10

The Trump administration’s actions have effectively halted USAID-funded clinical research worldwide, creating an unprecedented situation with significant ethical, legal, and medical implications. Clinical trials that relied on USAID funding have stopped, leaving ongoing research in limbo and raising serious concerns about what happens to trial participants and who bears responsibility for any resulting harm. Key Legal and Ethical Questions: 1. Who is the sponsor? If the U.S. government was ...

en-us

2:29

Ebola Vaccine Trial in Record Time!

DarshanTalks Podcast ·

2025/02/08

On January 30, 2025, Uganda confirmed an outbreak of the Ebola Sudan virus, and in an unprecedented global first, a clinical trial to assess the efficacy of a vaccine against the virus was launched within just four days. This rapid response was made possible by proactive planning following a 2022 outbreak, during which the Ugandan Ministry of Health, Makerere University, and the Uganda Virus Research Institute implemented a strategy to fast-track future trial activations. By pre-selecting inv...

en-us

0:50

Your Clinical Trial Site M&A Agreement is Exposing...

DarshanTalks Podcast ·

2025/02/07

When working on an M&A transaction involving a clinical trial site, it's crucial to thoroughly review vendor agreements. It's not just about what is included, but what is missing. For example, do you have the right quality and privacy agreements in place, or are you unknowingly exposing yourself to liability? If there’s a lack of necessary agreements, it’s important to assess whether it’s due to ignorance or an oversight that could lead to future legal risks. If you're unsure, reach out t...

en-us

1:01

What Does ICH E6 R3 Say About Returning Data to...

DarshanTalks Podcast ·

2025/02/05

The most recent ICH E6(R3) final guidance introduces critical updates to Good Clinical Practice (GCP), particularly around informed consent and participant data access. The guidance emphasizes greater flexibility and the use of technology-driven innovations to enhance how patients understand what they are consenting to. A significant update appears in section 2.8 (Investigator Responsibilities), which now requires a clear plan for returning trial-related data to participants when appropriate....

en-us

2:28

Navigating the Ongoing HHS Communication Freeze

DarshanTalks Podcast ·

2025/02/04

Now that we’ve passed February 1st, a key date for the potential easing of the freeze on all HHS communications, we find ourselves at February 3rd with no significant updates or changes. Despite expectations that restrictions might begin to lift, there has been no broad release of communications across federal agencies involved in clinical trials and regulatory oversight. While this does not provide definitive insight into the administration’s plans, it does confirm that, for now, the freeze ...

en-us

3:47

Ordinary People Are Changing Medicine

DarshanTalks Podcast ·

2025/02/03

Citizen biohacking is an empowering movement where individuals take medical innovation into their own hands, often stepping in when traditional medicine falls short. Driven by necessity, love, and a desire for survival, many have solved complex medical problems themselves, leading to groundbreaking discoveries. This trend raises important questions about safety, ethics, and the future of healthcare, with both promise and complexity. One of the most well-known examples is Lorenzo’s Oil, where ...

en-us

2:29

Trump’s First 10 Days: The Impact on Clinical Trials

DarshanTalks Podcast ·

2025/01/31

Edye Edens discusses how the first nine to ten days under the new administration have brought notable shifts for both healthcare and clinical research, particularly in regulatory compliance and funding. While remaining politically neutral, the focus is on understanding how these changes impact clinical trials and research oversight. A key update is that the federal communication freeze across health agencies is expected to ease by February 1, which should provide more clarity on the administr...

en-us

0:58

Selling a Business with Issues

DarshanTalks Podcast ·

2025/01/31

When selling a company, certain issues may arise that could concern potential buyers. Here's a breakdown of how to approach them:Price Adjustments: Some issues can be acknowledged, and the buyer may adjust the price accordingly, allowing the sale to proceed with minimal adjustments.Successor Liability: Issues like DOJ concerns or successor liability might require more attention, especially in asset-based transactions.Risk-Based Analysis: For less critical matters, such as design defects, you ...

en-us

11:44

Breaking Down GCP E6(R3)

DarshanTalks Podcast ·

2025/01/28

Darshan Kulkarni and Edye Edens discuss the latest update to Good Clinical Practice (GCP) guidelines, E6 R3, was explored. GCP, developed by the International Council for Harmonisation (ICH), provides globally accepted ethical and operational standards for conducting clinical trials. The 2025 update represents a significant revision since its last update in 2016, emphasizing technology, data integrity, and structural changes to accommodate rapid innovation in clinical research.Key Highlights ...

en-us

5:54

AdvaMed 7 rules for Essential AI Innovation

DarshanTalks Podcast ·

2025/01/25

Artificial intelligence (AI) is rapidly reshaping healthcare, with over 950 FDA-authorized AI devices transforming diagnosis, treatment, and administrative workflows. AdvaMed's new position paper emphasizes seven foundational principles to guide AI in medical technology development and regulation.Key Highlights:A Robust Regulatory Framework: AdvaMed urges alignment with international standards for AI-driven innovations while maintaining patient safety.Privacy and Data Transparency: Transparen...

en-us

1:21

Teva’s Case Should Shape Your Pharma Strategy

DarshanTalks Podcast ·

2025/01/22

Teva Pharmaceutical's $450 million settlement highlights the challenges of compliance in the pharmaceutical industry. The Department of Justice accused Teva of violating the anti-kickback statute and the False Claims Act by using co-payment assistance programs to steer Medicare payments for its drug Copaxone while raising prices. Additionally, Teva admitted to price-fixing schemes for generic drugs like pravastatin. This case serves as a stark reminder that compliance isn't just about avoidin...

en-us

8:10

🔒 AI’s Impact on Healthcare: Liability, Ethics, and...

DarshanTalks Podcast ·

2025/01/21

Subscriber-only episodeToday, we explore a pressing issue in the healthcare landscape: the liability associated with artificial intelligence (AI). As AI technologies transform healthcare—from diagnostic tools to treatment recommendations—it's crucial to understand the legal and ethical implications surrounding their use, particularly regarding accountability.AI systems can analyze vast amounts of data, providing insights that aid in diagnosing diseases and personalizing treatment plans. Howev...

en-us

331 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter